Compare SWBI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | PRTA |
|---|---|---|
| Founded | 1852 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 491.2M | 539.9M |
| IPO Year | 2000 | 2013 |
| Metric | SWBI | PRTA |
|---|---|---|
| Price | $14.86 | $10.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $14.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 625.0K | 453.1K |
| Earning Date | 03-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $474,661,000.00 | $814,000.00 |
| Revenue This Year | $7.61 | $1,111.38 |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | $296.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.73 | $4.32 |
| 52 Week High | $15.40 | $11.69 |
| Indicator | SWBI | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 62.55 | 67.15 |
| Support Level | $13.65 | $9.69 |
| Resistance Level | $15.24 | $10.90 |
| Average True Range (ATR) | 0.45 | 0.40 |
| MACD | -0.09 | 0.10 |
| Stochastic Oscillator | 74.90 | 96.87 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.